Mobile

A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms

Update Il y a 4 ans
Reference: EUCTR2004-002692-16

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

· To assess the anti-tumor activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with Indolent non-Hodgkin’s Lymphoid neoplasm, relapsing or refractory to a prior therapy

Inclusion criteria

  • Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory

Links